Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

Cancer vaccine experts are worried that if the Trump administration takes a hostile posture towards mRNA broadly, cancer ...

Eli Lilly, a renowned drug manufacturer, stated that its GLP-1 pill, orforglipron, assisted individuals in reducing 12.4% of their weight following 72 weeks in a late-stage study.The company ...

Eli Lilly shares fell as disappointing data on its new weight-loss pill overshadowed strong growth from the company’s current obesity medicine, which helped drive it to raise its yearly profit and ...

Live Updates Live Coverage Updates appear automatically as they are published. Discovery-ing Some Profits 9:40 am Continuing ...

Eli Lilly shares fell after orforglipron's Phase 3 data showed less weight loss than rival drugs, despite a strong Q2 ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

Eli Lilly and Company has confirmed it’s selling its 25,000-square-foot manufacturing site in Branchburg. The decision was ...

Shares of Eli Lilly & Co. (LLY) were tumbling in early trading Thursday, after the drug giant disclosed late-stage trial data for its weight-loss pill that fell well short of expectations. The data ...

People with obesity who took Eli Lilly's daily oral GLP-1 drug orforglipron lost an average of 12.4% of their body weight, ...

Chief Executive David Ricks said the quarter was marked by robust sales for Zepbound and Mounjaro, in addition to momentum across other key medicines. Eli Lilly logged net income of $5.66 billion, or ...